Permeon Biologics, a drug developer, has raised $2.5 million in venture capital and debt, according to a new filing by the company with the Securities and Exchange Commission.

Permeon aims to enhance human health by using its novel Intraphilin Technology Platform to enable intracellular biologics as a revolutionary new generation of therapeutic drugs.

Permeon's Intraphilin Technology Platform leverages supercharged proteins into intracellular biologics directly or by covalent conjugation or by complexing with active protein biologics and nucleic acids to create best-in-class, active therapeutic agents with potent intracellular activity and without cytotoxicity.